Search
for
Sort by
Research 391–420 of 527
- How Our Microbiome Influences the Pathogenesis of Alopecia Areata
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
- Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata
- Predominant expression of interleukin (IL)‐17 in chronic alopecia areata compared to IFN‐γ in pathogenic Th17 cells, tissue‐resident memory T cells and natural killer cells
- Lichen Planopilaris Responsive to a Novel Phytoactive Botanical Treatment: A Case Series
- Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
- Observation of the Expression of Vascular Endothelial Growth Factor and the Potential Effect of Promoting Hair Growth Treated with Chinese Herbal BeauTop
- Molecular Regulatory Mechanisms in Chicken Feather Follicle Morphogenesis
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Alopecia areata: a comprehensive review of clinical, immunologic, and genetic perspectives
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
- Gut microbiome, metabolome and alopecia areata
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Role and Mechanisms of Phytochemicals in Hair Growth and Health
- AIRE Deficiency Leads to the Development of Alopecia Areata‒Like Lesions in Mice
- Alopecia areata – Aktuelles Verständnis und Management
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
- Phytochemicals for Hair Health Targeting Growth Signaling Molecules in Hair Follicular Stem Cells: A New Strategy for Hair Growth
- Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- The Diverse Experiences and Challenges of Individuals With Alopecia Areata: Survey Results From Finland
- Inhibition of TNF-α-Induced Collagen Degradation and Oxidative Damage by Centipeda minima and Brevilin A in Human Dermal Fibroblasts
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives